| Autolus Therapeutics plc (AUTL) Q1 2024 Earnings Call Transcript | 05/17 12:55 | seekingalpha.com |
| Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates | 05/17 07:00 | globenewswire.com |
| Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress | 05/14 10:00 | globenewswire.com |
| Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO | 04/24 10:00 | globenewswire.com |
| Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024 | 04/23 07:00 | globenewswire.com |
| Autolus Therapeutics Announces Changes to its Board of Directors | 04/01 07:00 | globenewswire.com |
| Autolus Therapeutics plc (AUTL) Q4 2023 Earnings Call Transcript | 03/15 05:23 | seekingalpha.com |
| Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates | 03/14 07:00 | globenewswire.com |
| Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site | 03/12 07:00 | globenewswire.com |
| Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024 | 02/29 07:00 | globenewswire.com |